During the past decade, Sahlgrenska Sjukhuset; Neurology conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 2 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 1 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Sahlgrenska Sjukhuset; Neurology" are "Multiple Sclerosis, Relapsing-Remitting" (2 trials), "Multiple Sclerosis" (1 trials) and "Relapsing Multiple Sclerosis" (1 trials). Many other conditions were trialed in "Sahlgrenska Sjukhuset; Neurology" in a lesser frequency.

Most popular intervention types in "Sahlgrenska Sjukhuset; Neurology" are "Drug" (3 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Ocrelizumab" (4 trials), "Interferon beta-1a" (1 trials), "Interferon beta-1a-matching placebo" (1 trials) and "Ocrelizumab-matching placebo" (1 trials). Other intervention names were less common.

The vast majority of trials in "Sahlgrenska Sjukhuset; Neurology" are 4 trials for "All" genders.

Currently, there are NaN active trials in "Sahlgrenska Sjukhuset; Neurology". undefined are not yet recruiting, 1 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 2 completed trials in Sahlgrenska Sjukhuset; Neurology, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Sahlgrenska Sjukhuset; Neurology, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 4 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".